Illumina, Inc. (NASDAQ:ILMN) – Equities researchers at Svb Leerink lowered their Q2 2019 earnings per share (EPS) estimates for shares of Illumina in a research report issued on Wednesday, March 27th, Zacks Investment Research reports. Svb Leerink analyst P. Souda now expects that the life sciences company will post earnings of $1.51 per share for the quarter, down from their prior forecast of $1.52.
A number of other equities analysts have also recently weighed in on the company. UBS Group raised Illumina from a “neutral” rating to a “buy” rating and upped their price target for the stock from $340.00 to $370.00 in a report on Thursday, January 3rd. Morgan Stanley reduced their price target on Illumina from $320.00 to $288.00 and set an “equal weight” rating for the company in a report on Monday, January 7th. Leerink Swann raised Illumina to an “outperform” rating and reduced their price target for the stock from $380.00 to $365.00 in a report on Wednesday, January 30th. Deutsche Bank cut Illumina from a “buy” rating to a “hold” rating and set a $296.53 price target for the company. in a report on Friday, January 25th. Finally, Bank of America reaffirmed a “buy” rating and issued a $355.00 price target on shares of Illumina in a report on Wednesday, January 30th. Three research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Illumina presently has an average rating of “Buy” and an average price target of $346.97.
Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Tuesday, January 29th. The life sciences company reported $1.32 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.36 by ($0.04). The company had revenue of $867.00 million during the quarter, compared to analyst estimates of $865.33 million. Illumina had a net margin of 24.79% and a return on equity of 24.51%. The business’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same period last year, the firm earned $1.44 EPS.
Several hedge funds have recently bought and sold shares of ILMN. Vanguard Group Inc boosted its position in shares of Illumina by 1.8% during the third quarter. Vanguard Group Inc now owns 10,833,784 shares of the life sciences company’s stock worth $3,976,649,000 after buying an additional 188,516 shares during the period. Oregon Public Employees Retirement Fund boosted its position in shares of Illumina by 66,581.4% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 10,562,335 shares of the life sciences company’s stock worth $35,000 after buying an additional 10,546,495 shares during the period. Jennison Associates LLC boosted its position in shares of Illumina by 13.5% during the fourth quarter. Jennison Associates LLC now owns 5,479,564 shares of the life sciences company’s stock worth $1,643,486,000 after buying an additional 653,348 shares during the period. Capital International Investors purchased a new position in shares of Illumina during the third quarter worth $1,482,837,000. Finally, Geode Capital Management LLC boosted its position in shares of Illumina by 10.1% during the fourth quarter. Geode Capital Management LLC now owns 1,854,346 shares of the life sciences company’s stock worth $555,173,000 after buying an additional 170,046 shares during the period. Institutional investors and hedge funds own 90.46% of the company’s stock.
In other news, Director Robert S. Epstein sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, February 1st. The stock was sold at an average price of $280.11, for a total value of $280,110.00. Following the completion of the sale, the director now directly owns 4,256 shares in the company, valued at $1,192,148.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Omead Ostadan sold 1,260 shares of the company’s stock in a transaction that occurred on Friday, February 15th. The shares were sold at an average price of $294.62, for a total value of $371,221.20. Following the completion of the sale, the senior vice president now owns 29,534 shares of the company’s stock, valued at $8,701,307.08. The disclosure for this sale can be found here. Insiders sold 34,826 shares of company stock valued at $10,604,560 over the last 90 days. Company insiders own 0.38% of the company’s stock.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Featured Article: Understanding Price to Earnings Ratio (PE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.